Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. - Wikidata - awgldk - TriplyDB

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

http://www.wikidata.org/entity/Q34608222

about

Treatment of gastric cancer Chemotherapy in Elderly Patients with Gastric Cancer A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.Capecitabine in gastric cancer.Chemotherapy for patients with advanced gastric cancer with performance status 2 Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Treatment options in patients with metastatic gastric cancer: current status and future perspectives Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis.Recent advances in the HER2 targeted therapy of gastric cancer S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis Predictive value of in vitro adenosine triphosphate-based chemotherapy response assay in advanced gastric cancer patients who received oral 5-Fluorouracil after curative resection.Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial.Gastric cancer and the epoch of immunotherapy approaches Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy.D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy.Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study Chemotherapy for advanced gastric cancer: review and update of current practices.A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial.Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma.Accomplishments in 2008 in the management of localized gastric cancer ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience.Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.Management of advanced gastric cancer.Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.Optimal chemotherapy for advanced gastric cancer: is there a global consensus?Capecitabine in the treatment of esophageal and gastric cancers.How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.Exceptional Response to Systemic Therapy in Advanced Metastatic Gastric Cancer: A Case Report.

P2860

Q24602875-A2F3A1FE-964E-49C4-8CA0-5D76BE4837F7 Q26771424-0CC2869B-AB9A-4607-B3B3-4CF19D6E5987 Q33391384-C9AF8AC4-9B20-4B55-847D-474DB164BB3D Q33399530-BBDF57A8-E0B0-48F3-88ED-A1CBFB935A2D Q33415971-33EE1013-E35E-43CA-BC51-7A7F0606C0F2 Q33429869-8047228C-D37F-4345-B697-382284E66E22 Q33430668-4806C22C-56D2-4EAB-8AA0-50180D68E4D3 Q33831232-6526088F-2FDF-4B7C-93B8-814D85B632BA Q33849656-BB7E7AA9-9BBF-4B8E-BECD-924D9F2AA611 Q34236005-1258B6D9-E2F7-4B74-9C7E-0BB64C16E57B Q34395962-342B0DD8-CC80-49E8-B945-FDAC5E772C2A Q34507843-04410A76-49A8-4D6B-9983-8B56064F0C65 Q34620678-706FA102-1681-402F-93F3-D34CF9F80FCD Q34656353-8257DD31-8720-42D3-87B3-4E895EAD77BE Q34661367-35BE1F3E-C4ED-4B9C-9EBB-BA450EB93B0B Q34761656-19942337-E9E5-425C-9F8B-934824C8E1AF Q34967104-CCD86BCD-CB95-4624-BB87-3E8ED3B30E57 Q35070531-247D67D6-2D44-4361-BEE2-1E9AB7382D1B Q35083334-9F1A8497-6DCE-4246-9005-5A13ECC6654B Q35113001-83944CA4-3850-48DE-840D-87B63D2A5FF5 Q35620673-D8CCD4BB-B4BC-47E3-930B-483B0F9EE23B Q35625349-E4A114DA-BA8E-4C07-934B-9A4C147F856E Q36306250-F091EFB6-BE76-42C9-B8FB-53C251ECD9EE Q36643077-E4C9D685-DD15-4E97-AE5C-9A9EBE61DD92 Q36767776-B2130681-67CF-40D5-A468-BD6814D4C4B8 Q37046529-906A81F7-56EE-4320-B60C-26D69B8B67BE Q37205013-047807D0-A6FD-4C77-B62D-330D493EC394 Q37208729-EDC8FB59-5D5A-4EE0-9806-0D6581F0F42E Q37468843-A1C82FCE-7C25-4789-A538-F5E088B200C8 Q37642780-1A1BBC8D-FE1B-428E-986E-E4272C907D49 Q37719600-AEDC4F6A-8EB6-4316-B88F-8E617DF8D4B7 Q37845734-D577E7E1-2116-453D-BFC6-8F4D8DAA3544 Q37858518-B303A64D-3B77-426E-9FC3-677E86A8813C Q37889959-2C980927-A20D-4103-8133-BDF47A5EB5F6 Q37989161-3961A34B-5981-4337-A26E-DFE7F4DF8298 Q38078288-A094994D-A943-473D-A3DF-64B00BA163A4 Q38139297-558F33D8-A658-443E-ABCC-09B164D51F8B Q38148794-719F931F-86B8-448D-9EA5-420A909E648E Q38241766-B8E4A3AC-333C-40B1-AE76-223F585B9310 Q38397658-5BDE5774-D802-4C94-8010-1983004A31E1

P2860

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

http://www.wikidata.org/entity/Q34608222

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@ast

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@en

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@nl

type

label

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@ast

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@en

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@nl

prefLabel

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@ast

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@en

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@nl

P1433

Q34608222-D7D44696-7C44-4FBB-A362-1792F894808F

P1476

Q34608222-CDBD115E-A6EF-4932-89EA-F3EC844FD089

P2093

Q34608222-3D1D0EB8-D346-4343-AF03-EA261202F659

Q34608222-9484C9D1-703B-44B4-91EE-6FE9B11491D7

Q34608222-B6E4DF7B-49D5-402C-A932-D479E101A474

Q34608222-E960E669-501E-45AE-AABF-7FDD9B7AF15B

P2860

Q34608222-126FAA82-8EDA-47E4-84B3-82BB116177E4

Q34608222-28503A9A-AB8A-4A00-A8B5-6286249C0AF5

Q34608222-2E5AD41B-7A5B-4023-BE0F-1F224E33F3B7

Q34608222-38D99F69-3319-4A28-88B5-E842C55CA042

Q34608222-3FC6E505-B077-4D80-A2C0-4207F5B9AD3C

Q34608222-40DD1D16-9F5E-4C89-B946-270AF68526B8

Q34608222-455B4C21-1928-4AE6-BBDF-4D907F55F40A

Q34608222-4D5F1864-A9C6-42C0-B0B3-43E4B4779609

Q34608222-6285A18D-1B11-473C-8345-C4E70CC30554

Q34608222-6ACA5937-6797-43C7-B3D7-18BEE025C4AE

P304

Q34608222-0FAEC54E-CE79-4578-B36E-F4E09343767C

P31

Q34608222-55332CC9-DFC4-473C-B3A8-497138122480

Q34608222-c4dccbd9-a5db-4edd-b864-956827301e21

P356

Q34608222-89C930D8-4C50-442B-BB34-E03974713DED

P433

Q34608222-E5AB722C-21CE-4A23-8D3C-9532EA84ECAB

P478

Q34608222-B0819031-E089-4C66-82A8-97FBC90BA0E0

P50

Q34608222-662C424C-CD7E-4B22-997C-73F9C9E5751A

P577

Q34608222-8F16006F-42DB-4618-9E14-5DC29D3C0353

P5875

Q34608222-01E42175-54B8-41B7-B924-A116FF3EEB84

P698

Q34608222-7143B84E-BF3A-4BCB-8342-D59D798CC311

P921

Q34608222-5309B03A-EB64-47F3-B188-3A4F2503427D

Q34608222-950AFAB8-42B9-4554-A81F-902FDCA36595

P356

P1433

Annals of Oncology

P1476

Meta-analysis of the REAL-2 an ...... nced oesophago-gastric cancer.

@en

P2093

A F C Okines

http://www.w3.org/2001/XMLSchema#string

A R Norman

http://www.w3.org/2001/XMLSchema#string

P McCloud

http://www.w3.org/2001/XMLSchema#string

Y-K Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.

Capecitabine: preclinical pharmacology studies.

Clinical pharmacokinetics of capecitabine.

Answering patients' needs: oral alternatives to intravenous therapy.

P304

1529-1534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP047

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

P577

2009-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26245472

http://www.w3.org/2001/XMLSchema#string

P698

19474114

http://www.w3.org/2001/XMLSchema#string

P921